All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
Studies have reported conflicting results on the benefit of rituximab in combination with chemotherapy in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). Here, we summarize the long-term results after a median follow-up of 82.3 months of phase III HOVON NHL 24 trial published by Bromberg et al.1 in Neuro-oncology investigating patients treated with methotrexate, BCNU (bis-chloroethylnitrosourea, carmustine), teniposide, and prednisolone (MBVP) with and without rituximab.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Consolidative HDC-ASCT versus non-myeloablative immunochemotherapy for patients with primary CNS lymphoma
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2022, Gerald Illerhaus presented results from...
Prof. Andres Ferreri | ASH 2017 | Key messages from treatment of primary CNS lymphoma session
Professor Andres Ferreri San Raffaele Hospital, Milan, IT Interview topic: Key messages from the educational session on treatment of primary CNS lymphoma
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox